Avalyn Pharma Inc. AVLN
—
28.08
(0.47)
(1.65%)
as of 25 Sep
- Market cap
- $1.3B
- P/E
- 0.0×
Follow AVLN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| (43.95%) | — | — | — | ||
ROIC |
(102.61%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(26.84%) | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(3.26) | 0.00 | — | 0.00 | |
Free Cash Flow |
(96.53) | — | — | — | |
Capital Expenditures |
(0.59) | — | — | — | |
Piotroski F-Score |
0.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(12.53%) | 0.00% | 0.00% | 0.00% | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
1.03 | — | — | — | |
Depreciation/Fixed assets |
(1.02) | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.48 | — | — | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(3.24) | 0.00 | — | 0.00 | |
Capex per Share |
(0.02) | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | — | — | — | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates